Canada Markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
243.06-0.07 (-0.03%)
At close: 04:02PM EST
242.30 -0.76 (-0.31%)
After hours: 07:55PM EST
Sign in to post a message.
  • S
    Samantha
    Gonna need this to go up soon
  • k
    kastenz
    CMS wants patients to be treated in clinical trials only, and mentions this will affect not only Biogen, but Lilly as well:

    Jan 11 (Reuters) - The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected.
    Biogen shares were down 7.3% at $224 in extended trading on Tuesday. Shares of Biogen's Japanese partner Eisai Co Ltd slid 2.6% in Tokyo.
    The decision from the U.S. Centers for Medicare and Medicaid Services (CMS), the health agency that runs Medicare, could change as it seeks comment from companies and patients. A final decision is due on April 11.
    The final CMS coverage terms are expected to apply to all drugs in the class, including experimental medications in development by Eli Lilly & Co, Roche Holding AG and Eisai.
    Patient advocacy group UsAgainstAlzheimer’s chairman George Vradenburg said he was angry Medicare placed conditions on the use of the drugs that were more limiting than the regulator, the Food and Drug Administration, put on Aduhelm, and that the Medicare decision applied to any amyloid drug.
  • k
    kastenz
    I own this, my top position - so I looked around and see these red flags that might have catalyzed this decline:

    Debt to equity 220%
    O'Neil bullish set-up, this has now often a bull trap.
    Schwab A rating, oddly enough this is not a good thing, I studied these ratings, A rated often do worse.

    None the less, this is a well managed company and has a bright future. I was well impressed by their prudent buy of Prevail, they did not pay an extravagant price for this unique approach to SD and more.
  • k
    kastenz
    Time for run up into ER early Feb
  • k
    kastenz
    LLY reported Donanemab Phase 2 results Jan-11. I don't believe the CMS action after the close will affect the commercialization of Donanemab, since Apr-11 is the key CMS date
  • k
    kastenz
    Entire move from 285 to 258 just an Elliot "ABC" correction, meaning important advance in the future.
  • E
    Eore
    Inside trading is only way to make money now: 1. Open company 2. Get listed 3. Manipulate 4. Collect!
  • A
    Anonymous
    Anonymous16 hours ago
    I keep hearing that Donanemab ,Lilly's drug is better than aduhelm so I went back to review the phase2 Trailblazer trial. Guess what-it's not.First,the inclusion criteria is specifically designed to optimize clinical effectiveness of donamemab. They require a specific tau concentration to be present one pet scanning. How specific-1955 pts were studied to identify just 272 who met the criteria its with the optimal amount of tau. They then randomized 126 its to placebo and 131 to investigational product. 49 pts receiving Donamemab(IP) discontinued therapy.Only 93 pts in placebo arm and 94pts receiving IP completed the trial. Compared that with the dropout rate in the OL sumifilam trial(<10%).Then the results: no statistical difference found in either Adas-cog or ADL. So what does Lilly do? They introduce their own proprietary end point`iADRS which is a composite of cog and ADL to optimize statistical outcome. They claim this is a valid endpoint ,but are only able to cite their own 2 prior research trials to justify its usage. In addition ,they note that pts treated with donamemab exhibited greater brain volume loss(not a good thing!) as well as 26 % with ARIA-E with 6% being symptomatic with resolution of symptoms requiring 18 weeks! All of you on this board are familiar with sava results. Does anyone think Lilly has anything more than a second coming of Aduhelm.And of course the FDA to save face ,has granted it BTD. There is only one real hope for AD pts( maybe 2 if Anavex would ever publish decipherable trial results) and that is sumifilam. C'mon FDA ,we've seen enough of your support of big Pharma. Its time to look out for the AD patients, not for your next private industry job
    Less
  • N
    ND
    I've been long LLY for a couple years now, but the current PE is troublesome for me. It's tempting to lock in some profits and buy back lower, but that is also risky. Hmmm... not sure
  • S
    Steve
    Anyone know the big drop in premarket today?? Thank you.
  • e
    ed
    Is there any hope here? Own the stock just below $240…. Stock is down $30 straight down.
  • M
    Masterly
    it has been quite a run since $35 ten years ago
  • I
    IPS STUFF
    any news anyone - drop over 7 point afterhours.
  • J
    JosephK
    Dividend increased 15%. That's what I wanted to hear. I need my grocery money monthly; so stocks without dividends are pretty much useless to me. If the majority of you out there had bought this at $34, would you still own it today? Probably not! Most of YOU would have closed out your position by $70 and virtually all of you by $100. This is just a different mindset. I would have been one of you 40 years ago too. I'm NOT bragging, I'm just letting you know that trading constantly should not be your sole strategy youngsters!
  • R
    RalphD
    $AVXL conversation
    Does anyone have a "scientific" opinion on $LLY AZ drug donanemab?

    Of course $LLY has the resources to expedite trials and influence the FDA.

    The drug seems to attack amyloids and tau. I did not see any mention about cognitive effects.

    While everyone looks at $SAVA, $LLY might be the fox.
  • S
    Samantha
    Good news in The Who approving lly drugs. Maybe that will get it moving
  • V
    Value_Riskman
    why is this dropping
  • R
    Rick
    Lilly over the last 26 years has almost made me a millionaire. A small $4,00 investment and reinvested dividends over the years and bingo a $600,00 valuation.
  • A
    Anonymous
    Yahoo analyst data is way out of date. It forecasted rev at $24B, EPS at 7s. But IBD's forecast at $27B and 8s for EPS. Now, Lilly updated its rev at $28B. EPS 8s. The market is happy to see the increase. The inaccurate data is misleading.
  • T
    TomV
    Now I’m a little disappointed. My gain dropped below 500%